Trial Profile
A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Selepressin (Primary)
- Indications Septic shock
- Focus Registrational; Therapeutic Use
- Acronyms SEPSIS-ACT
- Sponsors Ferring Pharmaceuticals
- 24 Dec 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 02 Oct 2019 Primary endpoint has not been met. (Vasopressor- and mechanical ventilator-free days)
- 02 Oct 2019 Results assessing effect of Selepressin vs Placebo in Patients With Septic Shock published in the JAMA: the Journal of the American Medical Association